 |
市場調查報告書
商品編碼
1991419
2026-2034年全球慢性阻塞性肺病和氣喘治療設備市場規模、佔有率、趨勢和成長分析報告Global COPD and Asthma Devices Market Size, Share, Trends & Growth Analysis Report 2026-2034 |
||||||
預計到 2034 年，慢性阻塞性肺病和氣喘醫療設備市場規模將從 2025 年的 472 億美元達到 713.1 億美元，並預計從 2026 年到 2034 年將以 4.69% 的複合年成長率成長。
受全球呼吸系統疾病盛行率不斷上升的推動，慢性阻塞性肺病（COPD）和氣喘治療設備的全球市場正經歷強勁成長。吸入器、霧化器和呼吸監測設備等設備在慢性呼吸系統疾病的管理中發揮著至關重要的作用。日益嚴重的空氣污染、吸菸習慣和環境因素導致呼吸系統疾病患者人數不斷增加。醫療專業人員正擴大採用先進的呼吸設備來改善患者治療和疾病管理。
慢性阻塞性肺病（COPD）和氣喘在成人和兒童中的日益加重負擔推動了市場成長。吸入治療設備的科技進步提高了藥物傳輸效率，也提升了患者的便利性。攜帶式、易用型設備越來越受歡迎，因為患者希望在醫療機構之外也能有效控制症狀。此外，人們健康意識的提高和早期診斷項目的推廣也促進了呼吸治療設備的普及。
鑑於醫療創新推動呼吸系統照護的持續進步，慢性阻塞性肺病（COPD）和氣喘治療設備市場前景依然光明。智慧吸入器和數位化監測系統有望實現更有效的疾病追蹤和治療依從性。遠端醫療和遠端患者監護的普及將進一步提升患者管理水準。隨著醫療系統致力於改善呼吸系統疾病的治療效果，對先進的COPD和氣喘治療設備的需求預計將會成長。
目錄
第1章：引言
第2章執行摘要
第3章 市場變數、趨勢與框架
- 市場譜系展望
- 滲透率和成長前景分析
- 價值鏈分析
- 法律規範
- 標準與合規性
- 監管影響分析
- 市場動態
- 市場促進因素
- 市場限制因素
- 市場機遇
- 市場挑戰
- 波特五力分析
- PESTLE分析
第4章 全球慢性阻塞性肺病和氣喘治療設備市場：依產品分類
- 市場分析、洞察與預測
- 吸入器
- 噴霧器
第5章 全球慢性阻塞性肺病和氣喘治療設備市場：依適應症分類
- 市場分析、洞察與預測
- 氣喘
- COPD
第6章 全球慢性阻塞性肺病和氣喘治療設備市場：依通路分類
- 市場分析、洞察與預測
- 零售藥房
- 醫院
- 網路藥房
第7章 全球慢性阻塞性肺病和氣喘治療設備市場：依地區分類
- 區域分析
- 北美市場分析、洞察與預測
- 美國
- 加拿大
- 墨西哥
- 歐洲市場分析、洞察與預測
- 英國
- 法國
- 德國
- 義大利
- 俄羅斯
- 其他歐洲國家
- 亞太市場分析、洞察與預測
- 印度
- 日本
- 韓國
- 澳洲
- 東南亞
- 其他亞太國家
- 拉丁美洲市場分析、洞察與預測
- 巴西
- 阿根廷
- 秘魯
- 智利
- 其他拉丁美洲國家
- 中東和非洲市場分析、洞察與預測
- 沙烏地阿拉伯
- UAE
- 以色列
- 南非
- 其他中東和非洲國家
第8章 競爭情勢
- 最新趨勢
- 公司分類
- 供應鏈和銷售管道合作夥伴（根據現有資訊）
- 市場佔有率和市場定位分析（基於現有資訊）
- 供應商情況（基於現有資訊）
- 策略規劃
第9章：公司簡介
- 主要公司的市佔率分析
- 公司簡介
- GF Health Products Inc
- Koninklijke Philips NV（Philips）
- 3M Company
- Boehringer Ingelheim International GmbH
- PARI Medical Holding GMBH
- AstraZeneca PLC
- Smith's Group Plc
- Aerogen Inc
- Baxter International Inc
- GlaxoSmithKline Plc
- Novartis AG
The COPD and Asthma Devices Market size is expected to reach USD 71.31 Billion in 2034 from USD 47.20 Billion (2025) growing at a CAGR of 4.69% during 2026-2034.
The global COPD and asthma devices market has witnessed strong growth due to the increasing prevalence of respiratory diseases worldwide. Devices such as inhalers, nebulizers, and respiratory monitoring equipment play a crucial role in managing chronic respiratory conditions. Rising air pollution levels, smoking habits, and environmental factors have contributed to the growing number of individuals diagnosed with respiratory disorders. Healthcare providers are increasingly adopting advanced respiratory devices to improve patient treatment and disease management.
Market growth is driven by the rising burden of chronic obstructive pulmonary disease and asthma among both adults and children. Technological advancements in inhalation therapy devices have improved medication delivery and patient convenience. Portable and user-friendly devices are becoming more popular as patients seek effective ways to manage symptoms outside clinical settings. Increasing healthcare awareness and early diagnosis programs have also contributed to higher adoption of respiratory treatment devices.
The future outlook for the COPD and asthma devices market remains positive as healthcare innovation continues to improve respiratory care. Smart inhalers and digital monitoring systems may enable better disease tracking and treatment adherence. Expansion of telemedicine and remote patient monitoring could further enhance patient management. As healthcare systems focus on improving respiratory disease outcomes, demand for advanced COPD and asthma treatment devices is expected to rise.
MARKET SEGMENTATION
By Product
- Inhalers
- Nebulizers
By Indication
- Asthma
- COPD
By Distribution Channel
- Retail Pharmacies
- Hospitals
- Online Pharmacies
COMPANIES PROFILED
- GF Health Products Inc, Koninklijke Philips NV Philips, 3M Company, Boehringer Ingelheim International GmbH, PARI medical Holding GMBH, AstraZeneca PLC, Smiths Group Plc, Aerogen Inc, Baxter International Inc, GlaxoSmithKline Plc, Novartis AG
- We can customise the report as per your requirements.
TABLE OF CONTENTS
Chapter 1. PREFACE
- 1.1. Market Segmentation & Scope
- 1.2. Market Definition
- 1.3. Information Procurement
- 1.3.1 Information Analysis
- 1.3.2 Market Formulation & Data Visualization
- 1.3.3 Data Validation & Publishing
- 1.4. Research Scope and Assumptions
- 1.4.1 List of Data Sources
Chapter 2. EXECUTIVE SUMMARY
- 2.1. Market Snapshot
- 2.2. Segmental Outlook
- 2.3. Competitive Outlook
Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK
- 3.1. Market Lineage Outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Value Chain Analysis
- 3.4. Regulatory Framework
- 3.4.1 Standards & Compliance
- 3.4.2 Regulatory Impact Analysis
- 3.5. Market Dynamics
- 3.5.1 Market Drivers
- 3.5.2 Market Restraints
- 3.5.3 Market Opportunities
- 3.5.4 Market Challenges
- 3.6. Porter's Five Forces Analysis
- 3.7. PESTLE Analysis
Chapter 4. GLOBAL COPD AND ASTHMA DEVICES MARKET: BY PRODUCT 2022-2034 (USD MN)
- 4.1. Market Analysis, Insights and Forecast Product
- 4.2. Inhalers Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 4.3. Nebulizers Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 5. GLOBAL COPD AND ASTHMA DEVICES MARKET: BY INDICATION 2022-2034 (USD MN)
- 5.1. Market Analysis, Insights and Forecast Indication
- 5.2. Asthma Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 5.3. COPD Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 6. GLOBAL COPD AND ASTHMA DEVICES MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)
- 6.1. Market Analysis, Insights and Forecast Distribution Channel
- 6.2. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.3. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 7. GLOBAL COPD AND ASTHMA DEVICES MARKET: BY REGION 2022-2034 (USD MN)
- 7.1. Regional Outlook
- 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.2.1 By Product
- 7.2.2 By Indication
- 7.2.3 By Distribution Channel
- 7.2.4 United States
- 7.2.5 Canada
- 7.2.6 Mexico
- 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.3.1 By Product
- 7.3.2 By Indication
- 7.3.3 By Distribution Channel
- 7.3.4 United Kingdom
- 7.3.5 France
- 7.3.6 Germany
- 7.3.7 Italy
- 7.3.8 Russia
- 7.3.9 Rest Of Europe
- 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.4.1 By Product
- 7.4.2 By Indication
- 7.4.3 By Distribution Channel
- 7.4.4 India
- 7.4.5 Japan
- 7.4.6 South Korea
- 7.4.7 Australia
- 7.4.8 South East Asia
- 7.4.9 Rest Of Asia Pacific
- 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.5.1 By Product
- 7.5.2 By Indication
- 7.5.3 By Distribution Channel
- 7.5.4 Brazil
- 7.5.5 Argentina
- 7.5.6 Peru
- 7.5.7 Chile
- 7.5.8 Rest of Latin America
- 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.6.1 By Product
- 7.6.2 By Indication
- 7.6.3 By Distribution Channel
- 7.6.4 Saudi Arabia
- 7.6.5 UAE
- 7.6.6 Israel
- 7.6.7 South Africa
- 7.6.8 Rest of the Middle East And Africa
Chapter 8. COMPETITIVE LANDSCAPE
- 8.1. Recent Developments
- 8.2. Company Categorization
- 8.3. Supply Chain & Channel Partners (based on availability)
- 8.4. Market Share & Positioning Analysis (based on availability)
- 8.5. Vendor Landscape (based on availability)
- 8.6. Strategy Mapping
Chapter 9. COMPANY PROFILES OF GLOBAL COPD AND ASTHMA DEVICES INDUSTRY
- 9.1. Top Companies Market Share Analysis
- 9.2. Company Profiles
- 9.2.1 GF Health Products Inc
- 9.2.2 Koninklijke Philips N.V. (Philips)
- 9.2.3 3M Company
- 9.2.4 Boehringer Ingelheim International GmbH
- 9.2.5 PARI Medical Holding GMBH
- 9.2.6 AstraZeneca PLC
- 9.2.7 Smith's Group Plc
- 9.2.8 Aerogen Inc
- 9.2.9 Baxter International Inc
- 9.2.10 GlaxoSmithKline Plc
- 9.2.11 Novartis AG
